1. Home
  2. VSTD vs GRI Comparison

VSTD vs GRI Comparison

Compare VSTD & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VSTD

Vestand Inc.

N/A

Current Price

$0.29

Market Cap

4.1M

ML Signal

N/A

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

N/A

Current Price

$2.35

Market Cap

3.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VSTD
GRI
Founded
2016
2018
Country
United States
United States
Employees
259
5
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
3.3M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
VSTD
GRI
Price
$0.29
$2.35
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$160.00
AVG Volume (30 Days)
68.6K
37.3K
Earning Date
05-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$0.18
52 Week High
$2.20
$11.12

Technical Indicators

Market Signals
Indicator
VSTD
GRI
Relative Strength Index (RSI) 43.30 44.50
Support Level $0.21 $2.18
Resistance Level $0.37 $2.73
Average True Range (ATR) 0.02 0.22
MACD -0.00 -0.06
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
VSTD
GRI

About VSTD Vestand Inc.

Vestand Inc is a California-based fast-growing restaurant operator expanding into the real estate investment and development sector. It is a PropTech company engaged in AI-driven real estate investment and security token offerings (STOs). It provides services such as Property Acquisition, Property Development, Financial Management, and Property Management.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: